New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 9, 2013
11:26 EDTSGEN, TKPYYSeattle Genetics, Takeda report median OS 40.5 months in R/R HL with Adcetris
Seattle Genetics (SGEN) and Takeda Pharmaceutical (TKPYY) announced updated overall survival data from two ADCETRIS pivotal Phase 2 clinical trials in relapsed/refractory Hodgkin lymphoma, or R/R HL, and relapsed/refractory systemic anaplastic large cell lymphoma, or R/R sALCL, were presented at the 55th American Society of Hematology Annual Meeting taking place in New Orleans, LA, December 7-10. ADCETRIS is an antibody-drug conjugate directed to CD30. Median overall survival of 40.5 months was reported in R/R HL, and was not yet reached in R/R sALCL.
News For TKPYY;SGEN From The Last 14 Days
Check below for free stories on TKPYY;SGEN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
10:34 EDTTKPYYApricus Biosciences reports Takeda accepts first shipment of Vitaros
Subscribe for More Information
08:34 EDTSGENPiper Jaffray tech and biopharma analysts hold analyst/industry conference call
Technical Analyst Johnson, along with BioPharma Analysts, discuss the recent downturn in the biotech and specialty pharmaceuticals industries on an Analyst/Industry conference call to be held on April 17 at 10 am.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use